A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence

被引：0
作者：
Thatcher R. Heumann
Marina Baretti
Elizabeth A. Sugar
Jennifer N. Durham
Sheila Linden
Tamara Y. Lopez-Vidal
James Leatherman
Leslie Cope
Anup Sharma
Colin D. Weekes
Peter J. O’Dwyer
Kim A. Reiss
Dulabh K. Monga
Nita Ahuja
Nilofer S. Azad
机构：
[1] The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Departments of Biostatistics and Epidemiology
[2] The Bloomberg School of Public Health at Johns Hopkins,Yale Cancer Center
[3] Yale University School of Medicine,Abramson Cancer Center
[4] Massachusetts General Hospital Cancer Center,Medical Oncology
[5] University of Pennsylvania,undefined
[6] Allegheny General Hospital,undefined
来源：
Clinical Epigenetics | 2022年 / 14卷
关键词：
Pancreatic cancer; Epigenetic therapy; Clinical trial; Hypomethylation; Azacitidine; Maintenance therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
    Heumann, Thatcher R.
    Baretti, Marina
    Sugar, Elizabeth A.
    Durham, Jennifer N.
    Linden, Sheila
    Lopez-Vidal, Tamara Y.
    Leatherman, James
    Cope, Leslie
    Sharma, Anup
    Weekes, Colin D.
    O'Dwyer, Peter J.
    Reiss, Kim A.
    Monga, Dulabh K.
    Ahuja, Nita
    Azad, Nilofer S.
    CLINICAL EPIGENETICS, 2022, 14 (01)
  • [2] Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma
    Mesia, Ricard
    Bossi, Paolo
    Hansen, Aaron R.
    Hsieh, Ching-Yun
    Licitra, Lisa F.
    Tan, Eng-Huat
    Chen, Peng
    Miller, JulieAnn
    Siu, Lilian L.
    Haddad, Robert I.
    EUROPEAN JOURNAL OF CANCER, 2019, 123 : 138 - 145
  • [3] Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia
    Roboz, Gail J.
    Montesinos, Pau
    Selleslag, Dominik
    Wei, Andrew
    Jang, Jun-Ho
    Falantes, Jose
    Voso, Maria T.
    Sayar, Hamid
    Porkka, Kimmo
    Marlton, Paula
    Almeida, Antonio
    Mohan, Sanjay
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Skikne, Barry
    Kantarjian, Hagop
    FUTURE ONCOLOGY, 2016, 12 (03) : 293 - 302
  • [4] A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors
    Gaillard, Stephanie L.
    Zahurak, Marianna
    Sharma, Anup
    Durham, Jennifer N.
    Reiss, Kim A.
    Sartorius-Mergenthaler, Susan
    Downs, Melinda
    Anders, Nicole M.
    Ahuja, Nita
    Rudek, Michelle A.
    Azad, Nilofer
    CANCER, 2019, 125 (16) : 2837 - 2845
  • [5] An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
    Taylor, Kirsty
    Yau, Helen Loo
    Chakravarthy, Ankur
    Wang, Ben
    Shen, Shu Yi
    Ettayebi, Ilias
    Ishak, Charles A.
    Bedard, Philippe L.
    Razak, Albiruni Abdul
    Hansen, Aaron R.
    Spreafico, Anna
    Cescon, Dave
    Butler, Marcus O.
    Oza, Amit M.
    Lheureux, Stephanie
    Stjepanovic, Neda
    Van As, Brendan
    Boross-Harmer, Sarah
    Wang, Lisa
    Pugh, Trevor J.
    Ohashi, Pamela S.
    Siu, Lillian L.
    De Carvalho, Daniel D.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [6] Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma:: a randomized phase II trial
    Scheithauer, W
    Schüll, B
    Ulrich-Pur, H
    Schmid, K
    Raderer, M
    Haider, K
    Kwasny, W
    Depisch, D
    Schneeweiss, B
    Lang, F
    Kornek, GV
    ANNALS OF ONCOLOGY, 2003, 14 (01) : 97 - 104
  • [7] A Phase II/III Trial of Oral Azacitidine (Oral-AZA) in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Santini, Valeria
    Fenaux, Pierre
    Suzuki, Takahiro
    Sekeres, Mikkael A.
    He, Jun
    Barkalifa, Ronit
    Vigil, Carlos E.
    Prebet, Thomas
    Komrokji, Rami
    Giagounidis, Aristoteles
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S364 - S364
  • [8] A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma
    Park, Byeong-Bae
    Park, Joon Oh
    Lee, Hyo Rak
    Lee, Jeeyun
    Choi, Dong Wook
    Choi, Seong-Ho
    Heo, Jin Seok
    Lee, Jong Kyun
    Lee, Kyu Taek
    Lim, Do Hoon
    Park, Young Suk
    Lim, Ho-Yeong
    Kang, Won Ki
    Park, Keunchil
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (04) : 489 - 494
  • [9] A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma
    Byeong-Bae Park
    Joon Oh Park
    Hyo Rak Lee
    Jeeyun Lee
    Dong Wook Choi
    Seong-Ho Choi
    Jin Seok Heo
    Jong Kyun Lee
    Kyu Taek Lee
    Do Hoon Lim
    Young Suk Park
    Ho-Yeong Lim
    Won Ki Kang
    Keunchil Park
    Cancer Chemotherapy and Pharmacology, 2007, 60 : 489 - 494
  • [10] A Randomized Phase II Trial of Adjuvant Chemotherapy With Uracil/Tegafur and Gemcitabine Versus Gemcitabine Alone in Patients With Resected Pancreatic Cancer
    Yoshitomi, Hideyuki
    Togawa, Akira
    Kimura, Fumio
    Ito, Hiroshi
    Shimizu, Hiroaki
    Yoshidome, Hiroyuki
    Otsuka, Masayuki
    Kato, Atsushi
    Nozawa, Satoshi
    Furukawa, Katsunori
    Miyazaki, Masaru
    CANCER, 2008, 113 (09) : 2448 - 2456
12345